Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) have been given a consensus recommendation of “Hold” by the nine research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $14.00.

A number of research firms have weighed in on TTPH. HC Wainwright began coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price on the stock. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $8.00 to $15.00 in a report on Wednesday, July 26th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 30th. BMO Capital Markets reissued an “outperform” rating and issued a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Finally, BidaskClub raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd.

In other news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the transaction, the insider now owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 33,405 shares of company stock worth $199,691 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Candriam Luxembourg S.C.A. raised its stake in shares of Tetraphase Pharmaceuticals by 95.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 393,000 shares of the biopharmaceutical company’s stock worth $2,688,000 after buying an additional 192,000 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of Tetraphase Pharmaceuticals by 54.4% in the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock worth $17,470,000 after buying an additional 900,000 shares during the period. EcoR1 Capital LLC bought a new position in shares of Tetraphase Pharmaceuticals in the second quarter worth about $4,516,000. State Street Corp raised its stake in shares of Tetraphase Pharmaceuticals by 6.4% in the second quarter. State Street Corp now owns 725,094 shares of the biopharmaceutical company’s stock worth $5,165,000 after buying an additional 43,561 shares during the period. Finally, PDT Partners LLC raised its stake in shares of Tetraphase Pharmaceuticals by 22.0% in the second quarter. PDT Partners LLC now owns 191,952 shares of the biopharmaceutical company’s stock worth $1,369,000 after buying an additional 34,665 shares during the period. 40.92% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.36 on Friday.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. During the same period in the prior year, the company posted ($0.58) earnings per share. The company’s quarterly revenue was up 355.6% on a year-over-year basis. analysts anticipate that Tetraphase Pharmaceuticals will post -2.87 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/04/tetraphase-pharmaceuticals-inc-ttph-given-average-recommendation-of-hold-by-brokerages.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.